|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,941.10 INR | -0.66% |
|
+0.44% | +12.87% |
| 07-21 | South Africa regulator reviews 12 generic semaglutide applications | RE |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| Market Cap | 4,657B 48.36B 42.48B 39.5B 36.25B 68.11B 69.16B 469B 183B 2,290B 182B 178B 7,917B | P/E 2027 * |
35.6x | P/E 2028 * | 30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,394B 45.63B 40.07B 37.27B 34.2B 64.26B 65.25B 443B 173B 2,160B 171B 168B 7,469B | EV / Sales 2027 * |
6.72x | EV / Sales 2028 * | 5.93x |
| Free-Float |
44.39% | Yield 2027 * |
0.82% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.66% | ||
| 1 week | +0.44% | ||
| Current month | +4.22% | ||
| 1 month | +3.56% | ||
| 3 months | +19.79% | ||
| 6 months | +18.95% | ||
| Current year | +12.87% |
| 1 week | 1,925.2 |  | 1,966.5 |
| 1 month | 1,855.9 | | 1,966.5 |
| Current year | 1,583.7 | | 1,966.5 |
| 1 year | 1,548 | | 1,966.5 |
| 3 years | 1,068.35 | | 1,966.5 |
| 5 years | 672.55 | | 1,966.5 |
| 10 years | 312 | | 1,966.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 31/08/2025 | |
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 31/08/2025 | |
| Director/Board Member | 73 | 24/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.66% | +0.44% | +14.72% | +76.40% | 48.36B | |
| +2.20% | +1.41% | +61.04% | +111.43% | 35.8B | |
| +1.26% | -0.57% | -5.20% | +34.48% | 11.83B | |
| -0.46% | -3.06% | +14.15% | +80.63% | 11.48B | |
| -0.37% | -0.37% | +37.89% | +137.78% | 9.01B | |
| +1.52% | +0.39% | +48.79% | -5.82% | 6.99B | |
| -0.17% | -2.92% | +13.13% | +30.45% | 6.7B | |
| -0.59% | -1.95% | +2.23% | +178.07% | 6.42B | |
| -7.92% | -13.61% | -34.97% | -4.08% | 5.3B | |
| -2.05% | -1.46% | +20.49% | +136.46% | 4.37B | |
| Average | -0.72% | -2.05% | +17.23% | +77.58% | 14.63B | |
| Weighted average by Cap. | +0.05% | -0.48% | +25.21% | +83.01% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.79B 5.97B 5.55B 5.09B 9.57B 9.72B 65.9B 25.75B 322B 25.51B 24.96B 1,112B | 730B 7.58B 6.66B 6.19B 5.68B 10.67B 10.84B 73.49B 28.71B 359B 28.45B 27.83B 1,240B |
| Net income | 132B 1.37B 1.21B 1.12B 1.03B 1.93B 1.96B 13.31B 5.2B 64.97B 5.15B 5.04B 225B | 156B 1.62B 1.42B 1.32B 1.21B 2.28B 2.32B 15.72B 6.14B 76.72B 6.08B 5.95B 265B |
| Net Debt | -263B -2.74B -2.4B -2.23B -2.05B -3.85B -3.91B -26.53B -10.37B -130B -10.27B -10.05B -448B | -329B -3.41B -3B -2.79B -2.56B -4.81B -4.88B -33.1B -12.93B -162B -12.81B -12.54B -559B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | ₹1,941.10 | -0.66% | 1,578,929 |
| 23/07/26 | ₹1,954.00 | +0.57% | 2,057,288 |
| 22/07/26 | ₹1,943.00 | -0.96% | 1,718,430 |
| 21/07/26 | ₹1,961.90 | +0.28% | 1,412,579 |
| 20/07/26 | ₹1,956.40 | +1.23% | 1,676,034 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
